Home » Stocks » NBIO

Nascent Biotech Inc. (NBIO)

Stock Price: $0.0951 USD -0.0042 (-4.23%)
Updated Jul 26, 2021 9:53 AM EDT - Market open
Market Cap 10.34M
Revenue (ttm) 750,000
Net Income (ttm) n/a
Shares Out 107.73M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $0.0951
Previous Close $0.0993
Change ($) -0.0042
Change (%) -4.23%
Day's Open 0.0965
Day's Range 0.0951 - 0.0965
Day's Volume 2,000
52-Week Range 0.0437 - 0.1540

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, CA / ACCESSWIRE / July 13, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a biotechnology company pioneering innovative medicines to overcome diff...

2 weeks ago - Accesswire

VERO BEACH, FL / ACCESSWIRE / June 15, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of mo...

1 month ago - Accesswire

SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of mono...

1 month ago - Accesswire

TAIZHOU, ZHEJIANG, CHINA & SAN DIEGO, CA / ACCESSWIRE / May 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech ("Nascent" or the "Company"...

2 months ago - Accesswire

SAN DIEGO, CA / ACCESSWIRE / May 4, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoc...

2 months ago - Accesswire

SAN DIEGO, CA / ACCESSWIRE / April 26, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of mo...

3 months ago - Accesswire

SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of mo...

3 months ago - Accesswire

SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of mo...

4 months ago - Accesswire

SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of mon...

4 months ago - Accesswire

Nascent Biotech Inc (OTCMKTS: NBIO) has announced the publication of promising in-vitro study results from its pritumumab (PTB) research collaboration with Syracuse University, validating the potential ...

5 months ago - Benzinga

About NBIO

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a monoclonal antibody to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as lung and breast cancer metastases to the brain; and pancreatic cancer. The company is based in Vero Beach, Florida.

Industry
Biotechnology
Stock Exchange
OTCMKTS
Ticker Symbol
NBIO
Full Company Profile

Financial Performance

Financial Statements